Iron oxide and gold bimetallic radiosensitizers for synchronous tumor chemoradiation therapy in 4T1 breast cancer murine model

2021 ◽  
Author(s):  
Hamed Nosrati ◽  
Yasamin Baghdadchi ◽  
Reza Abbasi ◽  
Murat Barsbay ◽  
Mohammadreza Ghaffarlou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Iron Oxide ◽  
Cancer Therapy ◽  
Therapeutic Effect ◽  
Murine Model ◽  
Chemoradiation Therapy ◽  
Synchronous Tumor ◽  
Multifunctional Nanomaterials ◽  
4T1 Breast Cancer

The development of highly integrated multifunctional nanomaterials with a superadditive therapeutic effect and good safety is an urgent but challenging task in cancer therapy research.

Paclitaxel‐Loaded Iron Oxide Nanoparticles for Targeted Breast Cancer Therapy

2019 ◽  
Vol 2 (12) ◽  
pp. 1900081 ◽  
Author(s):  
Mike Jeon ◽  
Guanyou Lin ◽  
Zachary R. Stephen ◽  
Frances L. Kato ◽  
Miqin Zhang
Keyword(s):  
Breast Cancer ◽  
Iron Oxide ◽  
Cancer Therapy ◽  
Iron Oxide Nanoparticles ◽  
Oxide Nanoparticles ◽  
Breast Cancer Therapy

scholarly journals Direct Comparison of Chol-siRNA Polyplexes and Chol-DsiRNA Polyplexes Targeting STAT3 in a Syngeneic Murine Model of TNBC

2022 ◽  
Vol 8 (1) ◽  
pp. 8
Author(s):  
Zhen Ye ◽  
Mai Mohamed Abdelmoaty ◽  
Stephen M. Curran ◽  
Shetty Ravi Dyavar ◽  
Devendra Kumar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Rna Interference ◽  
Cancer Therapy ◽  
Solid Tumors ◽  
Diblock Copolymer ◽  
Murine Model ◽  
Target Gene ◽  
Breast Tumors ◽  
Final Dose ◽  
Polymer Complexes

RNA interference (RNAi) molecules have tremendous potential for cancer therapy but are limited by insufficient potency after intravenous (IV) administration. We previously found that polymer complexes (polyplexes) formed between 3′-cholesterol-modified siRNA (Chol-siRNA) or DsiRNA (Chol-DsiRNA) and the cationic diblock copolymer PLL[30]-PEG[5K] greatly increase RNAi potency against stably expressed LUC mRNA in primary syngeneic murine breast tumors after daily IV dosing. Chol-DsiRNA polyplexes, however, maintain LUC mRNA suppression for ~48 h longer after the final dose than Chol-siRNA polyplexes, which suggests that they are the better candidate formulation. Here, we directly compared the activities of Chol-siRNA polyplexes and Chol-DsiRNA polyplexes in primary murine 4T1 breast tumors against STAT3, a therapeutically relevant target gene that is overexpressed in many solid tumors, including breast cancer. We found that Chol-siSTAT3 polyplexes suppressed STAT3 mRNA in 4T1 tumors with similar potency (half-maximal ED50 0.3 mg/kg) and kinetics (over 96 h) as Chol-DsiSTAT3 polyplexes, but with slightly lower activity against total Stat3 protein (29% vs. 42% suppression) and tumor growth (11.5% vs. 8.6% rate-based T/C ratio) after repeated IV administration of equimolar, tumor-saturating doses every other day. Thus, both Chol-siRNA polyplexes and Chol-DsiRNA polyplexes may be suitable clinical candidates for the RNAi therapy of breast cancer and other solid tumors.

scholarly journals Direct Comparison of Chol-siRNA Polyplexes and Chol-DsiRNA Polyplexes Targeting STAT3 in a Syngeneic Murine Model of TNBC

2021 ◽  
Author(s):  
Zhen Ye ◽  
Mai Mohamed Abdelmoaty ◽  
Stephen M. Curran ◽  
Shetty Ravi Dyavar ◽  
Devendra Kumar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Rna Interference ◽  
Cancer Therapy ◽  
Solid Tumors ◽  
Diblock Copolymer ◽  
Murine Model ◽  
Target Gene ◽  
Breast Tumors ◽  
Final Dose ◽  
Polymer Complexes

RNA interference (RNAi) molecules have tremendous potential for cancer therapy but are limited by insufficient potency after i.v. administration. We previously found that polymer complexes (polyplexes) formed between 3’-cholesterol-modified siRNA (Chol-siRNA) or DsiRNA (Chol-DsiRNA) and the cationic diblock copolymer PLL[30]-PEG[5K] greatly increase RNAi potency against stably expressed LUC mRNA in primary syngeneic murine breast tumors after daily i.v. dosing. Chol-DsiRNA Polyplexes, however, maintain LUC mRNA suppression ~48 h longer after the final dose than Chol-siRNA Polyplexes, suggesting they are a better candidate formulation. Here, we directly compared the activities of Chol-siRNA and Chol-DsiRNA Polyplexes in primary murine 4T1 breast tumors against STAT3, a therapeutically relevant target gene overexpressed in many solid tumors including breast cancer. We found that Chol-siSTAT3 Polyplexes suppressed STAT3 mRNA in 4T1 tumors with similar potency (half-maximal ED50 0.3 mg/kg) and kinetics over 96 hours as Chol-DsiSTAT3 Polyplexes but with slightly lower activity against total Stat3 protein (29% vs. 42% suppression) and tumor growth (11.5% vs. 8.6% rate-based T/C ratio) after repeated i.v. administration of tumor-saturating doses every other day. Thus, both Chol-siRNA Polyplexes and Chol-DsiRNA Polyplexes may be suitable clinical candidates for RNAi therapy of breast cancer and other solid tumors.

Enhancement of therapeutic effect in breast cancer with a steroid-conjugated ruthenium complex

2019 ◽  
Vol 43 (8) ◽  
pp. 3419-3427 ◽  
Author(s):  
Gaochao Lv ◽  
Ling Qiu ◽  
Ke Li ◽  
Qingzhu Liu ◽  
Xi Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Therapeutic Effect ◽  
Antitumor Effect ◽  
Ruthenium Complex ◽  
Breast Cancer Therapy ◽  
Positive Breast Cancer

A hybrid metallic prodrug for targeting PR-positive breast cancer therapy was prepared, which revealed significantly in vivo antitumor effect.

Sign in / Sign up

Export Citation Format

Share Document